By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Life Technologies announced after the close of the market on Wednesday that it has made an equity investment in Synthetic Genomics, the firm behind research by Craig Venter and colleagues that resulted in the first functional bacterial cells controlled by a synthetic genome.

Terms of the investment were not disclosed.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A survey examines how age, political leanings, and more influence how Americans view certain scientific topics, the Associated Press reports.

A researcher who pleaded guilty to making false statements in research reports has been sentenced to four and a half years in prison and must pay $7.2 million back to the NIH.

The BabySeq project to study the risks and benefits of sequencing newborns is underway.

In Nature this week: association between genome-wide homozygosity and traits like height and cognitive ability, improved CRISPR-Cas9 editing, and more.